Talk:Rivaroxaban

From Wikipedia, the free encyclopedia

This is the talk page for discussing improvements to the Rivaroxaban article.

Article policies
Rivaroxaban is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome.
Start This article has been rated as start-Class on the quality scale.
High This article has been rated as high-importance for this Project's importance scale.

Although this drug is still under development, it may well become what ximelagatran could not: a safe oral anticoagulant that does not require monitoring. Comments invited. JFW | T@lk 09:02, 21 December 2005 (UTC)

If that is your opinion, you should not mention Ximelagatran as related drug. Otherwise readers could get the intention that both medications have similar mode of actions. German Wiki-User, 7 December 2007. —Preceding unsigned comment added by 212.64.224.241 (talk) 10:23, 7 December 2007 (UTC)

Rhone-Poulenc (PMID 10348709) and Lilly (PMID 10715155) tried doing this, but it seems Bayer is winning. JFW | T@lk 00:07, 30 May 2006 (UTC)
Unless Boehringer-Ingelheim manage to market BIBR 1048 (dabigatran) first... JFW | T@lk 00:43, 30 May 2006 (UTC)
BI are also working on BIBT 986, a thrombin/factor X dual inhibitor. JFW | T@lk 09:37, 21 June 2006 (UTC)

[edit] Paper to read

PMID 16859389 discusses all factor X inhibitors. JFW | T@lk 07:07, 6 September 2006 (UTC)

PMID 17379841 does too. JFW | T@lk 20:41, 5 April 2007 (UTC)

[edit] New papers

PMID 17244773 - body weight leads to minimal changes in plasma levels. JFW | T@lk 20:15, 20 May 2007 (UTC)

PMID 16198660 - initial pharmacokinetics studies. JFW | T@lk 20:17, 20 May 2007 (UTC)

[edit] Pubmed search

All results of rivaroxaban (to update rapidly). JFW | T@lk 15:38, 21 September 2007 (UTC)